A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.

Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB

The Journal of clinical endocrinology and metabolism1 Oct 2002Cited by 239 (Europe PMC)

PMID12364430DOI10.1210/jc.2002-020334PepBankPUB-12364430

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide increased lumbar spine BMD more than alendronate at 3 months.
In plain wordsIn women with osteoporosis, teriparatide increased spine bone density more than alendronate at 3 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD at three months
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 14 monthsAs given in this study (human).
Source sentences
Summary
At 3 months, teriparatide increased lumbar spine BMD significantly more than did alendronate (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 micro g plus oral placebo (n = 73) or oral alendronate…
Report a problemFND-1236443001
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, lumbar spine BMD increased 12.2% with teriparatide versus 5.6% with alendronate.
In plain wordsIn women with osteoporosis, teriparatide increased spine bone density more than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 14 monthsAs given in this study (human).
Measurements
Lumbar spine BMD increase
12.2%
Teriparatide
Lumbar spine BMD increase
5.6%
Alendronate
Source sentences
Summary
Lumbar spine-BMD increased by 12.2% in the teriparatide group and 5.6% in the alendronate group (P < 0.001 teriparatide vs. alendronate).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 micro g plus oral placebo (n = 73) or oral alendronate…
Report a problemFND-1236443002
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide increased femoral neck BMD more than alendronate.
In plain wordsIn women with osteoporosis, teriparatide increased femoral neck bone density more than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 14 monthsAs given in this study (human).
Source sentences
Summary
Teriparatide increased femoral neck BMD and total body bone mineral significantly more than did alendronate, but BMD at the one third distal radius decreased, compared with alendronate (P < or = 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 micro g plus oral placebo (n = 73) or oral alendronate…
Report a problemFND-1236443003
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide increased total body bone mineral more than alendronate.
In plain wordsIn women with osteoporosis, teriparatide increased total body bone mineral more than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal body bone mineral
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 14 monthsAs given in this study (human).
Source sentences
Summary
Teriparatide increased femoral neck BMD and total body bone mineral significantly more than did alendronate, but BMD at the one third distal radius decreased, compared with alendronate (P < or = 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 micro g plus oral placebo (n = 73) or oral alendronate…
Report a problemFND-1236443004
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide decreased distal radius BMD compared with alendronate.
In plain wordsIn women with osteoporosis, teriparatide decreased distal radius bone density compared with alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseDistal radius BMD
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 14 monthsAs given in this study (human).
Source sentences
Summary
Teriparatide increased femoral neck BMD and total body bone mineral significantly more than did alendronate, but BMD at the one third distal radius decreased, compared with alendronate (P < or = 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 micro g plus oral placebo (n = 73) or oral alendronate…
Report a problemFND-1236443005
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, nonvertebral fractures were less frequent with teriparatide than alendronate.
In plain wordsIn women with osteoporosis, fractures outside the spine were less frequent with teriparatide than alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fractures
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg once daily · subcutaneous · Median 14 monthsAs given in this study (human).
Source sentences
Summary
Nonvertebral fracture incidence was significantly lower in the teriparatide group than in the alendronate group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 micro g plus oral placebo (n = 73) or oral alendronate…
Report a problemFND-1236443006
07HumanRandomized controlled trialSafety outcome
In postmenopausal women with osteoporosis, both teriparatide and alendronate were well tolerated.
In plain wordsIn women with osteoporosis, both teriparatide and alendronate were well tolerated.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableTolerability
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Adverse events · Whole body
Studied dose
40 microg once daily · subcutaneous · Median 14 monthsAs given in this study (human).
Source sentences
Summary
Both treatments were well tolerated despite transient mild asymptomatic hypercalcemia with teriparatide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 micro g plus oral placebo (n = 73) or oral alendronate…
Report a problemFND-1236443008
08HumanRandomized controlled trialSafety outcome
In postmenopausal women with osteoporosis, teriparatide caused transient mild asymptomatic hypercalcemia.
In plain wordsIn women with osteoporosis, teriparatide caused temporary mild high blood calcium without symptoms.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableHypercalcemia
Study
n = 73
Outcome group
Adverse events · Endocrine and hormones
Studied dose
40 microg once daily · subcutaneous · Median 14 monthsAs given in this study (human).
Source sentences
Summary
Both treatments were well tolerated despite transient mild asymptomatic hypercalcemia with teriparatide treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared the effects of teriparatide and alendronate sodium on BMD, nonvertebral fracture incidence, and bone turnover in 146 postmenopausal women with osteoporosis. Women were randomized to either once-daily sc injections of teriparatide 40 micro g plus oral placebo (n = 73) or oral alendronate…
Report a problemFND-1236443007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.